Same active ingredient (tirzepatide); different products with different FDA-approved indications. Mounjaro: type 2 diabetes. Zepbound: chronic weight management plus, since December 2024, moderate-to-severe OSA in adults with obesity — the first drug ever FDA-approved for OSA.
Side-by-side
| Dimension | Mounjaro | Zepbound |
|---|---|---|
| Editorial score | 0/100 | 0/100 |
| Semaglutide | T2D · ~$1,069/mo list | Weight + OSA · ~$1,059/mo list |
| Tirzepatide | — | — |
Who should pick Mounjaro
Patients with type 2 diabetes — Mounjaro. Most commercial insurance covers Mounjaro for T2D.
Who should pick Zepbound
Patients with obesity (without diabetes), or obesity with moderate-to-severe OSA — Zepbound under the December 2024 OSA indication.
Frequently asked
Same drug?
Same active ingredient (tirzepatide). Different products with different FDA-approved indications.
Does Zepbound work for OSA?
Yes. SURMOUNT-OSA showed AHI reduction ~30 events/hr at 52 weeks. Zepbound is the first drug FDA-approved for OSA.
Which is cheaper?
List prices similar (~$1,000–$1,100/mo). Lilly Direct vial program is lower. Compounded tirzepatide (NexLife $186/mo) is substantially lower.